In the last trading session, 0.64 million shares of the Elevation Oncology Inc (NASDAQ:ELEV) were traded, and its beta was 1.40. Most recently the company’s share price was $0.45, and it changed around -$0.03 or -5.28% from the last close, which brings the market valuation of the company to $26.82M. ELEV currently trades at a discount to its 52-week high of $5.83, offering almost -1195.56% off that amount. The share price’s 52-week low was $0.47, which indicates that the current value has fallen by an impressive -4.44% since then.
Elevation Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended ELEV as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Elevation Oncology Inc is expected to report earnings per share of -0.22 for the current quarter.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Instantly ELEV has showed a red trend with a performance of -5.28% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5980 on recent trading dayincreased the stock’s daily price by 24.75%. The company’s shares are currently down -19.36% year-to-date, but still down -15.32% over the last five days. On the other hand, Elevation Oncology Inc (NASDAQ:ELEV) is -34.55% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 95.0% from its current value. Analyst projections state that ELEV is forecast to be at a low of $8 and a high of $10.
Elevation Oncology Inc (ELEV) estimates and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -52.56%. Elevation Oncology Inc earnings are expected to increase by 36.80% in 2025, but the outlook is positive 11.33% per year for the next five years.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
FARALLON CAPITAL MANAGEMENT LLC, with 6.0971% or 3.6 million shares worth $9.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 1.64 shares worth $0.75 million, making up 2.77% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.38 shares worth around $0.63 million, which represents about 2.34% of the total shares outstanding.
